| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Vyvgart Hytrulo vs Gammagard Liquid
Side-by-side clinical, coverage, and cost comparison for polyradiculoneuropathy, chronic inflammatory demyelinating.Deep comparison between: Vyvgart Hytrulo vs Gammagard Liquid with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGammagard Liquid has a higher rate of injection site reactions vs Vyvgart Hytrulo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Gammagard Liquid but not Vyvgart Hytrulo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Vyvgart Hytrulo
Gammagard Liquid
At A Glance
SC injection
Once weekly
FcRn blocker
IV infusion or SC injection
Every 3-4 weeks (IV) or weekly (SC)
Immune globulin replacement
Indications
- Myasthenia Gravis, Generalized
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Multifocal motor neuropathy
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Dosing
Myasthenia Gravis, Generalized 1,000 mg efgartigimod alfa/10,000 units hyaluronidase SC once weekly for 4-week cycles (prefilled syringe over 20-30 seconds) or 1,008 mg/11,200 units (vial over 30-90 seconds); subsequent cycles based on clinical evaluation.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1,000 mg efgartigimod alfa/10,000 units hyaluronidase SC once weekly (prefilled syringe over 20-30 seconds) or 1,008 mg/11,200 units (vial over 30-90 seconds); continue based on clinical response.
Primary Immunodeficiency (IV) 300-600 mg/kg every 3-4 weeks by IV infusion; start at 0.5 mL/kg/hr, increase every 30 minutes if tolerated up to 5 mL/kg/hr.
Primary Immunodeficiency (SC) Initial dose 1.37 x previous IV dose divided by weeks between IV doses, given weekly; 20-30 mL/site at 20-30 mL/hr/site (>=40 kg) or 20 mL/site at 15-20 mL/hr/site (<40 kg).
Multifocal Motor Neuropathy 0.5-2.4 g/kg/month by IV infusion; start at 0.5 mL/kg/hr, may increase if tolerated up to 5.4 mL/kg/hr.
Chronic Inflammatory Demyelinating Polyneuropathy Induction 2 g/kg divided over 2-5 consecutive days, then maintenance 1 g/kg divided over 1-4 consecutive days every 3 weeks by IV infusion; start at 0.5 mL/kg/hr, may increase if tolerated up to 5.4 mL/kg/hr.
Contraindications
- Serious hypersensitivity to efgartigimod alfa products, hyaluronidase, or any excipient of VYVGART HYTRULO (including anaphylaxis and hypotension leading to syncope)
- Anaphylactic or severe systemic hypersensitivity to human immune globulin
- IgA deficiency with antibodies to IgA and history of hypersensitivity
Adverse Reactions
Most common (>=10%) Injection site reactions (rash, erythema, pruritus, bruising, pain, urticaria), headache
Serious Infections, hypersensitivity reactions (including anaphylaxis and hypotension), infusion/injection-related reactions
Postmarketing Hypersensitivity reactions including anaphylaxis and hypotension, infusion/injection-related reactions, worsening of CIDP symptoms when transitioning from intravenous immunoglobulin treatment
Most common (>=5%) - Primary Immunodeficiency (IV) Headache, fatigue, pyrexia, nausea, chills, rigors, pain in extremity, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, pharyngolaryngeal pain, rash, arthralgia, myalgia, edema peripheral, pruritus, cardiac murmur
Most common (>=5%) - Primary Immunodeficiency (SC) Infusion site events, headache, fatigue, heart rate increased, pyrexia, abdominal pain upper, nausea, vomiting, asthma, blood pressure systolic increased, diarrhea, ear pain, aphthous stomatitis, migraine, oropharyngeal pain, pain in extremity
Most common (>=5%) - Multifocal Motor Neuropathy Headache, chest discomfort, muscle spasms, muscular weakness, nausea, oropharyngeal pain, pain in extremity
Most common (>=5%) - Chronic Inflammatory Demyelinating Polyneuropathy Headache, pyrexia, anemia, leukopenia, neutropenia, illness, blood creatinine increased, dizziness, migraine, somnolence, tremor, nasal dryness, abdominal pain upper, vomiting, chills, nasopharyngitis, pain in extremity
Serious Aseptic meningitis (IV for PI), pulmonary embolism, blurred vision (MMN)
Postmarketing Hemolysis, anaphylactic shock, cerebrovascular accident, transient ischemic attack, tremor, myocardial infarction, deep vein thrombosis, hypotension, pulmonary embolism, pulmonary edema, hyperhidrosis, chest pain, transfusion-related acute lung injury, hypersensitivity, myalgia, chills
Pharmacology
Efgartigimod alfa, a human IgG1 Fc fragment, binds to the neonatal Fc receptor (FcRn) and reduces circulating IgG; co-formulated hyaluronidase transiently depolymerizes hyaluronan to increase subcutaneous tissue permeability for 24 to 48 hours.
GAMMAGARD LIQUID supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial and viral agents and contains antibodies that interact with immune system cells; the mechanism in CIDP may include immunomodulatory effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Vyvgart Hytrulo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Gammagard Liquid
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
UnitedHealthcare
Vyvgart Hytrulo
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Gammagard Liquid
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Vyvgart Hytrulo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Gammagard Liquid
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Vyvgart Hytrulo.
No savings programs available for Gammagard Liquid.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Vyvgart HytruloView full Vyvgart Hytrulo profile
Gammagard LiquidView full Gammagard Liquid profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.